Gilbert's helps Mylan be first to market with generic galantamine

Gilbert's LLP represented Mylan Pharmaceutical ULC in overcoming a dosage regimen patent to become first to market with a generic galantamine ER product (used in the treatment of Alzheimers).  On November 10, 2010, the Federal Court found Canadian Patent No. 2,310,950 to be invalid as a method of medical treatment and also made findings of obvoiusness and a lack of a sound prediction.  The Federal Court of Appeal dismissed Janssen Inc.'s appeal for mootness on January 17, 2011.  Click to access the Federal Court trial decision and the Federal Court of Appeal dismissal.

(by Nathaniel Lipkus)